David F. Mcdermott
#118,648
Most Influential Person Now
David F. Mcdermott's AcademicInfluence.com Rankings
David F. Mcdermottphilosophy Degrees
Philosophy
#5286
World Rank
#8046
Historical Rank
Logic
#2589
World Rank
#3601
Historical Rank
Download Badge
Philosophy
David F. Mcdermott's Degrees
- Doctorate Medicine Stanford University
Why Is David F. Mcdermott Influential?
(Suggest an Edit or Addition)David F. Mcdermott's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Improved survival with ipilimumab in patients with metastatic melanoma. (2010) (13093)
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (2012) (10640)
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. (2015) (4550)
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients (2014) (4187)
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma (2018) (2700)
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. (2015) (2383)
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. (2018) (2082)
- Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. (2014) (2043)
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009) (1682)
- Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. (2015) (1015)
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. (2012) (963)
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. (2015) (926)
- Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. (2005) (857)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (750)
- Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. (2016) (730)
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. (2016) (703)
- Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. (2005) (632)
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial (2019) (611)
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma (2016) (500)
- Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. (2016) (495)
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma (2014) (475)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. (2019) (473)
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. (2015) (464)
- Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer (2005) (405)
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. (2015) (400)
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. (2013) (394)
- PD-1 as a potential target in cancer therapy (2013) (381)
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. (2017) (334)
- The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. (2011) (328)
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (2020) (324)
- Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab (2019) (316)
- Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. (2007) (315)
- Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. (2014) (310)
- Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. (2017) (308)
- Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. (2003) (303)
- Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. (2000) (291)
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. (2018) (273)
- Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies (2009) (268)
- Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. (2016) (261)
- Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. (2008) (257)
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). (2014) (253)
- Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses (2004) (250)
- Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America (2010) (249)
- PD-L1 expression in nonclear-cell renal cell carcinoma. (2014) (246)
- Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016) (243)
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma (2015) (239)
- Histologic Predictors of Renal Cell Carcinoma Response to Interleukin-2-Based Therapy (2005) (238)
- Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial (2020) (234)
- Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma (2010) (225)
- Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. (2015) (210)
- Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanoma (2006) (210)
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors (2014) (209)
- Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma (2016) (208)
- Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) (2008) (203)
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. (2018) (201)
- CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. (2017) (201)
- Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. (2017) (200)
- Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis (1994) (198)
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) (2018) (189)
- BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. (2012) (182)
- Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. (2014) (182)
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma (2013) (174)
- Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. (2020) (173)
- Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2014) (171)
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). (2013) (169)
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma (2016) (169)
- The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC) (2019) (158)
- High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade (2020) (157)
- Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. (1997) (156)
- Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma (2004) (149)
- Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. (2016) (148)
- Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors. (2015) (143)
- Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study (2018) (141)
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer. (2014) (137)
- Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors (2019) (136)
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. (2020) (134)
- Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. (2007) (134)
- Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. (2007) (133)
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2019) (130)
- Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (2020) (130)
- Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. (2021) (129)
- The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma (2014) (127)
- Long-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. (2014) (125)
- Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. (2003) (123)
- Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy (2016) (119)
- Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma (2015) (118)
- Checkpoint inhibitor immunotherapy in kidney cancer (2020) (117)
- Role and effect of IL-2 in experimental visceral leishmaniasis. (1993) (115)
- Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases (2009) (115)
- Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. (2011) (115)
- Vascular endothelial growth factor‐targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma (2010) (115)
- Phase I/II Study of Vaccination With Electrofused Allogeneic Dendritic Cells/Autologous Tumor-derived Cells in Patients With Stage IV Renal Cell Carcinoma (2007) (114)
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. (2019) (114)
- Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma (2020) (109)
- Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). (2013) (109)
- A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. (2002) (109)
- Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (2021) (97)
- Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma (2011) (97)
- The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). (2010) (96)
- Application of IL-2 and other cytokines in renal cancer (2004) (95)
- Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. (2010) (94)
- Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC) (2008) (91)
- CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups (2017) (90)
- Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427. (2018) (90)
- Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α (2009) (88)
- Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition (2017) (86)
- Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial (2016) (86)
- A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma. (2000) (84)
- Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. (2019) (84)
- Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition (2019) (84)
- COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma. (1988) (83)
- Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC). (2006) (82)
- Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review (2015) (79)
- BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804). (2015) (76)
- CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. (2019) (76)
- Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma (2016) (75)
- Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. (2010) (75)
- Expanded cohort results from CheckMate 016: A phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). (2015) (75)
- Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma (2015) (74)
- The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium. (2014) (74)
- Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. (2015) (74)
- Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). (2013) (73)
- A phase I/II study to assess the safety and efficacy of pazopanib (PAZ) and pembrolizumab (PEM) in patients (pts) with advanced renal cell carcinoma (aRCC). (2017) (73)
- A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). (2017) (71)
- Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: Survival and long-term safety in a phase I trial. (2013) (70)
- Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma. (2014) (69)
- Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). (2018) (68)
- VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma (2016) (68)
- Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. (2013) (67)
- Nivolumab for metastatic renal cell carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial. (2014) (66)
- Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma (2016) (66)
- Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma (2007) (64)
- Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma (2021) (63)
- IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). (2017) (63)
- irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial (2019) (62)
- Nivolumab for the treatment of cancer (2015) (61)
- Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma (2007) (61)
- Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma (2006) (59)
- A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma. (2011) (59)
- Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). (2019) (59)
- Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review (2010) (59)
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (2020) (58)
- Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma (2021) (57)
- Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. (2016) (57)
- The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy (2007) (56)
- An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0 (2018) (55)
- From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. (2021) (55)
- Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. (2013) (55)
- Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes (2017) (55)
- Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. (2020) (55)
- Axitinib (AG-013736) in patients with metastatic melanoma: A phase II study (2008) (54)
- Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. (2013) (53)
- Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC). (2015) (52)
- Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). (2020) (51)
- Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response. (2006) (51)
- The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. (1988) (50)
- Retrospective Analysis of the Safety and Efficacy of Interleukin-2 After Prior VEGF-targeted Therapy in Patients With Advanced Renal Cell Carcinoma (2009) (50)
- Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (2016) (50)
- Angiopoietin 2 Is a Potential Mediator of High-Dose Interleukin 2–Induced Vascular Leak (2007) (50)
- Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. (2020) (49)
- First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B. (2019) (49)
- A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts). (2006) (49)
- CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. (2015) (48)
- FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer (2013) (48)
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events (2018) (46)
- Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). (2020) (45)
- A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States (2014) (44)
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. (2022) (44)
- Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma (2022) (44)
- Potential of New Therapies like Anti-PD1 in Kidney Cancer (2014) (44)
- Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab (2019) (43)
- Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program (2010) (43)
- Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. (2020) (43)
- The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma. (2009) (42)
- Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. (2021) (41)
- First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. (2017) (41)
- Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma (2018) (41)
- Autosomal Dominant Epidermodysplasia Verruciformis Lacking a Known EVER1 or EVER2 Mutation (2009) (40)
- Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis (2011) (40)
- Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study (2018) (40)
- Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma (2015) (40)
- Retracted: Immunotherapy of metastatic renal cell carcinoma (2009) (39)
- Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition—A Pooled Analysis of Patients With Advanced Melanoma (2019) (39)
- Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. (2011) (39)
- Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference (2007) (39)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). (2020) (38)
- Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. (2010) (38)
- Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). (2012) (38)
- Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. (2012) (38)
- Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. (2015) (38)
- Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features (2008) (37)
- CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC). (2016) (37)
- KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1 (2020) (37)
- A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. (2010) (36)
- Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape (2014) (35)
- Effectiveness of treatment guidance on diarrhea and colitis across ipilimumab studies. (2011) (35)
- A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. (2016) (34)
- A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies. (2011) (34)
- Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer (2000) (34)
- Carbonic Anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. (2004) (34)
- Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results (2016) (32)
- A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma (2016) (32)
- Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. (2015) (32)
- Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis. (2019) (32)
- Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. (2016) (31)
- KEYNOTE-427 cohort B: First-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC). (2019) (31)
- Genitourinary tumors, non-prostate (2012) (31)
- Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review (2013) (30)
- 809OIMMUNE CORRELATES AND LONG TERM FOLLOW UP OF A PHASE IA STUDY OF MPDL3280A, AN ENGINEERED PD-L1 ANTIBODY, IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (30)
- Immunotherapy for metastatic renal cell carcinoma (2007) (29)
- The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? (2019) (29)
- First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. (2021) (29)
- Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (The ESPN Trial): A multicenter randomized phase 2 trial. (2014) (29)
- Randomized phase II study of dacarbazine with or without sorafenib in patients with advanced melanoma (2007) (29)
- Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): Association of biomarkers with clinical outcomes. (2015) (29)
- Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM (2016) (29)
- PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. (2014) (28)
- LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial (2022) (28)
- Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET (2010) (28)
- Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC). (2020) (28)
- Cytotoxic T-lymphocyte antigen-4 blockade in melanoma. (2015) (28)
- Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry (2019) (28)
- Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC). (2020) (27)
- Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry (2017) (27)
- Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma (2020) (27)
- Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. (2019) (26)
- Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes. (2015) (26)
- A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study (2013) (26)
- Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma (2015) (25)
- Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma (2018) (25)
- Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. (2019) (24)
- The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration. (2010) (24)
- The application of high-dose interleukin-2 for metastatic renal cell carcinoma (2009) (24)
- Safety and efficacy of sorafenib in elderly patients (pts) ≥65 years: A subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America (2008) (24)
- The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy (2012) (24)
- 661P Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC) (2021) (24)
- Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma (2022) (24)
- Final analysis of the CheckMate 025 trial comparing nivolumab (NIVO) versus everolimus (EVE) with >5 years of follow-up in patients with advanced renal cell carcinoma (aRCC). (2020) (23)
- Overall survival in patients with advanced melanoma (MEL) who discontinued treatment with nivolumab (NIVO) plus ipilimumab (IPI) due to toxicity in a phase II trial (CheckMate 069). (2016) (23)
- Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. (2010) (23)
- PD-L 1 expression in nonclear-cell renal cell carcinoma (2014) (23)
- Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials. (2006) (23)
- 1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (23)
- Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study. (2016) (23)
- Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study. (2009) (22)
- Soluble PD-L1 as an early marker of progressive disease on nivolumab (2022) (22)
- Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma. (2009) (22)
- Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study (2013) (21)
- A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. (2012) (21)
- Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). (2012) (21)
- ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features. (2016) (21)
- A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. (1998) (21)
- Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma (2014) (20)
- Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. (2018) (20)
- A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma (2008) (20)
- Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (20)
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression (2017) (20)
- KEYNOTE-427 cohort A: Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC). (2018) (20)
- An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. (2018) (20)
- First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A. (2019) (20)
- Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours (2019) (20)
- Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE). (2020) (19)
- Immune therapy for kidney cancer: a second dawn? (2013) (19)
- Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients (2014) (19)
- To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease (2019) (19)
- 711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy (2020) (19)
- Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics (2013) (19)
- Vascular endothelial growth factor and programmed death‐1 pathway inhibitors in renal cell carcinoma (2019) (19)
- PD-L1 expression in non-clear cell renal cell carcinoma. (2014) (19)
- Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference (2009) (19)
- Inadequacy of predicted creatinine clearance as guide to chemotherapy. (1987) (19)
- Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). (2021) (19)
- 1050OPHASE I STUDY OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (18)
- A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC). (2013) (18)
- First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. (2021) (18)
- The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study. (2021) (17)
- Improving End-of-Life Care: Palliative Care Embedded in an Oncology Clinic Specializing in Targeted and Immune-Based Therapies. (2017) (17)
- First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B (2019) (17)
- Interferon, interleukin-2, and other cytokines. (2014) (17)
- A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status (2017) (17)
- Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma (2020) (16)
- Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with previously treated metastatic renal cell carcinoma (mRCC). (2012) (16)
- Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. (2018) (16)
- A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy (2021) (16)
- International cancer seminars: a focus on kidney cancer. (2016) (16)
- A phase I-II study of rituximab, ifosfamide, mitoxantrone and etoposide (R-IME) for B cell non-Hodgkin's lymphoma prior to and after high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT). (2003) (16)
- Management of metastatic renal cell carcinoma in patients with poor prognosis (2010) (16)
- Re-induction with ipilimumab, gp100 peptide vaccine, or a combination of both from a phase III, randomized, double-blind, multicenter study of previously treated patients with unresectable stage III or IV melanoma. (2010) (16)
- Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study (2016) (16)
- Combinations of Bevacizumab With Immune Checkpoint Inhibitors in Renal Cell Carcinoma (2018) (15)
- Immunotherapy for renal cell carcinoma. (2011) (15)
- Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma. (2020) (15)
- Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. (2010) (15)
- A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies (2016) (15)
- The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2) (2014) (15)
- Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis (2018) (15)
- 2622 A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC) (2015) (14)
- A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). (2009) (14)
- Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC). (2015) (14)
- Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma (2004) (14)
- PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). (2019) (14)
- Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. (2016) (13)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (13)
- Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC. (2019) (13)
- Integrative clinical and molecular characterization of translocation renal cell carcinoma. (2022) (13)
- Retrospective analysis of interleukin-2 therapy in patients with metastatic renal cell carcinoma who had received prior antiangiogenic therapy (2008) (13)
- Melanoma and other skin tumors (2012) (13)
- Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. (2012) (13)
- Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial (2021) (13)
- Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. (2012) (13)
- Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms (2017) (13)
- Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC). (2018) (12)
- Immunotherapy of Metastatic Renal Cell Carcinoma (2008) (12)
- Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214. (2019) (12)
- Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC). (2018) (12)
- A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. (2021) (12)
- Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma (2020) (12)
- Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma (2019) (12)
- Abstract CT002: Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL) (2016) (12)
- A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma. (2014) (12)
- A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC). (2017) (12)
- A first-in-human phase I/II trial of the oral HIF-2a inhibitor PT2977 in patients with advanced RCC (2019) (12)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214. (2019) (12)
- Combined blockade of vascular endothelial growth factor and programmed death 1 pathways in advanced kidney cancer. (2017) (12)
- Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma (2020) (11)
- CheckMate 025: a randomized, open-label, phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC) (2015) (11)
- 713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of CheckMate 214 (2020) (11)
- Phase II trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. (2010) (11)
- Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) (2022) (11)
- Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma (2018) (11)
- High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR). (2014) (11)
- Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. (2021) (11)
- Abstract CT081: Molecular correlates of differential response to Atezolizumab +/- Bevacizumab vs Sunitnib in a Phase II study in untreated metastatic renal cell carcinoma (RCC) patients (2017) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two (2016) (11)
- Ipilimumab (IPI) Expanded Access Program (EAP) for Patients (PTS) with Stage III/IV Melanoma: Safety Data by Subgroups (2012) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Immunotherapy and targeted therapy combinations in renal cancer. (2011) (10)
- Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between Interleukin-2 complete and non-responders (2008) (10)
- Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma (2020) (10)
- A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆ (2021) (10)
- Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication. (2013) (10)
- Clinical and economic outcomes of treatment sequences for intermediate- to poor-risk advanced renal cell carcinoma. (2020) (10)
- More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma. (2007) (10)
- Refining indications for contemporary surgical treatment of renal cell carcinoma metastatic to the pancreas. (2009) (10)
- Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies. (2013) (10)
- Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. (2016) (10)
- FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma (2016) (9)
- TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). (2019) (9)
- First-line pembrolizumab (pembro) monotherapy in advanced non-clear cell renal cell carcinoma (nccRCC): Updated follow-up for KEYNOTE-427 cohort B. (2020) (9)
- Outcomes of PD-1/PD-L1 responders who discontinue therapy for immune-related adverse events (irAEs): Results of a cohort of patients (pts) with metastatic renal cell carcinoma (mRCC). (2017) (9)
- Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). (2012) (9)
- Phase II study of synthadotin (SYN-D; ILX651) administered daily for 5 consecutive days once every 3 weeks (qdx5q3w) in patients (Pts) with inoperable locally advanced or metastatic melanoma. (2004) (9)
- NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma (2018) (9)
- Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma. (2011) (9)
- Checkpoint inhibitors in metastatic papillary renal cell carcinoma. (2021) (9)
- A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. (2015) (8)
- Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry. (2014) (8)
- A phase I/II study to assess the safety and efficacy of pazopanib and MK-3475 in subjects with advanced renal cell carcinoma. (2014) (8)
- Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma (2021) (8)
- Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer (2011) (8)
- Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. (2021) (8)
- Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era (2017) (8)
- ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: Phase II experience (2005) (8)
- Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. (2020) (8)
- Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). (2017) (8)
- High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma (2020) (8)
- Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. (2018) (8)
- Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma (2020) (8)
- First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A (2019) (8)
- A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. (2018) (8)
- Plasma cell problems: Case 1. Disseminated cutaneous plasmacytomas treated with total skin electron radiotherapy. (2005) (7)
- Multiple host defense defects in failure of C57BL/6 ep/ep (pale ear) mice to resolve visceral Leishmania donovani infection (1996) (7)
- Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). (2017) (7)
- Correlation of response with overall survival (OS) for nivolumab vs everolimus in advanced renal cell carcinoma (aRCC): Results from the phase III CheckMate 025 study. (2016) (7)
- Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427. (2020) (7)
- Ipilimumab plus nivolumab (Ipi/Nivo) as salvage therapy in patients with immunotherapy (IO)-refractory metastatic renal cell carcinoma (mRCC). (2019) (7)
- Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade (2022) (7)
- Failure of initial VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC): What next? (2009) (7)
- Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. (2022) (7)
- Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. (2019) (7)
- Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. (2001) (7)
- Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma. (2020) (6)
- Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. (2021) (6)
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). (2019) (6)
- Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward (2017) (6)
- Anti-PD-1 (BMS-936558/MDX-1106/ONO-4538) in Patients With Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
- Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2 (2016) (6)
- Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Solid Tumors: Clinical Activity, Safety, and Molecular Markers (2012) (6)
- ECOG 1808: Randomized phase II trial of sunitinib with or without gemcitabine in advanced kidney cancer with sarcomatoid features. (2016) (6)
- A phase I dose-finding study of sunitinib (SU) in combination with gemcitabine (G) in patients (pts) with advanced solid tumors (2008) (6)
- Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). (2019) (6)
- Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (2017) (6)
- Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067 (2021) (6)
- A phase 1b dose-escalation study of TRC105 (endoglin antibody) in combination with axitinib in patients with metastatic renal cell carcinoma (mRCC) (2016) (6)
- Pembrolizumab (pembro) plus ipilimumab (ipi) or pegylated interferon alfa-2b (PEG-IFN) for advanced melanoma or renal cell carcinoma (RCC). (2016) (6)
- Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients (2019) (5)
- Improving the therapeutic index of IL-2. (2010) (5)
- 810ORANDOMIZED, DOSE-RANGING PHASE II TRIAL OF NIVOLUMAB FOR METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (5)
- Predicting early relapse in patients with BRAFV600E melanoma with a highly sensitive blood BRAF assay. (2012) (5)
- Treatment-free survival, with and without toxicity, as a novel outcome applied to immuno-oncology agents in advanced renal cell carcinoma (2019) (5)
- ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors. (2021) (5)
- Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. (2012) (5)
- A phase I trial of ALKS 4230, an engineered cytokine activator of NK and effector T cells, in patients with advanced solid tumors. (2017) (5)
- Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study (2007) (5)
- Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC). (2007) (5)
- Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry. (2016) (5)
- 1027MO ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumours (ARTISTRY-1) (2020) (5)
- Efficacy and safety of endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKI) after programmed cell death 1 (PD-1) inhibitor treatment in patients with metastatic clear cell renal cell carcinoma (mccRCC). (2015) (5)
- A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma. (2015) (5)
- Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71]. (2018) (5)
- Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): Phase 1 KEYNOTE-029 study. (2017) (5)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. (2022) (5)
- PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors. (2014) (5)
- Phase II study of the oral hypoxia-inducible factor 2α (HIF-2 α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC). (2020) (5)
- Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC). (2013) (5)
- Novel Immunotherapies in GU Malignancies (2013) (5)
- Phase Ib study of pembrolizumab and trebananib (angiopoietin-2 inhibitor [Ang-2]): Preliminary analysis of the colorectal cancer (CRC) cohort. (2019) (5)
- Improving Cancer Related Symptom Management with Collaborative Healthware (2004) (5)
- 1088PDLONG-TERM SURVIVAL OF IPILIMUMAB-NAïVE PATIENTS (PTS) WITH ADVANCED MELANOMA (MEL) TREATED WITH NIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN A PHASE 1 TRIAL. (2014) (5)
- FDG-PET as a predictive marker for therapy with everolimus in metastatic renal cell cancer (mRCC). (2011) (4)
- Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study (2019) (4)
- Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma? (2019) (4)
- TIVO-3: Final OS analysis of a phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC). (2020) (4)
- Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools (2006) (4)
- A phase II pilot trial of low dose, continuous infusion, or "metronomic", paclitaxel and oral celecoxib in patients with metastatic melanoma. (2006) (4)
- Abstract 2860: Improved clinical response in patients with advanced melanoma treated with nivolumab combined with ipilimumab compared to ipilimumab alone (2015) (4)
- A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer: sequential phase I/II studies (2001) (4)
- A multi-center phase II open-label study (CheckMate 204) to evaluate safety and efficacy of nivolumab (NIVO) in combination with ipilimumab (IPI) followed by NIVO monotherapy in patients (pts) with melanoma (MEL) metastatic to the brain. (2015) (4)
- Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Previously Treated, Metastatic Renal Cell Carcinoma (MRCC) (2012) (4)
- Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial (2021) (4)
- Combination of antiangiogenic therapy and cytotoxic chemotherapy for sarcomatoid renal cell carcinoma. (2013) (4)
- 3LBA CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC) (2015) (4)
- A phase Ia/IIb trial of the CXCR4 inhibitor X4P-001 and nivolumab for advanced renal cell carcinoma (RCC) that is unresponsive to nivolumab monotherapy. (2018) (4)
- Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma (2018) (4)
- Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes (2014) (4)
- Developing a model for embedded palliative care in a cancer clinic (2017) (4)
- Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. (2022) (4)
- Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214. (2021) (4)
- Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020. (2013) (4)
- First-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts) (2007) (4)
- Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. (2022) (4)
- Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside. (2015) (4)
- Patients with metastatic renal cell carcinoma (mRCC) receiving sunitinib in “real-world” clinical practice: Baseline characteristics and treatment efficacy (2008) (4)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B). (2021) (4)
- LBA39IMmotion150: Novel radiological endpoints and updated data from a randomized phase II trial investigating atezolizumab (atezo) with or without bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) (2017) (4)
- Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). (2012) (4)
- Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644). (2012) (4)
- Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment (2019) (4)
- CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy (2022) (3)
- Abstract B201: A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC) (2018) (3)
- Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2. (2016) (3)
- Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors. (2019) (3)
- Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. (2018) (3)
- Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma (mRCC) with severe renal impairment or on haemodialysis. (2009) (3)
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). (2019) (3)
- Immune checkpoint blockade in renal cell carcinoma (2016) (3)
- Neutrophil to lymphocyte ratio (NLR) and its effect on the prognostic value of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model for patients treated with targeted therapy (TT). (2014) (3)
- Case records of the Massachusetts General Hospital. Case 17-2008. A 63-year-old man with metastatic renal-cell carcinoma. (2008) (3)
- What is standard initial systemic therapy in metastatic renal cell carcinoma? (2007) (3)
- A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma. (2016) (3)
- Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIM HD IL-2 National Registry. (2015) (3)
- An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma (2022) (3)
- Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC) (2021) (3)
- Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. (2022) (3)
- Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade (2021) (3)
- Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. (2015) (3)
- 656MO Phase II study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, plus cabozantinib for treatment of advanced clear cell renal cell carcinoma (ccRCC) (2021) (3)
- Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. (2009) (3)
- A single-arm, open-label, U.S. expanded access study of vemurafenib in patients with metastatic melanoma. (2012) (3)
- Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. (2018) (2)
- Comparison of four tumor response criteria (RECIST 1.0, tumor shrinkage, radiodensity, and Choi) in assessing outcome to VEGF-targeted therapy in advanced renal cell carcinoma. (2010) (2)
- Targeting autophagy and immunotherapy with hydroxychloroquine and interleukin 2 in patients with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group study. (2018) (2)
- Treatment-free survival (TFS), a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma (AM). (2018) (2)
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression. (2017) (2)
- 1453P Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003 (2022) (2)
- TIVO-3: Tivozanib in patients with advanced renal cell carcinoma (aRCC) who have progressed after treatment with axitinib. (2021) (2)
- Sequential Decitabine and Dacarbazine in the Treatment of Melanoma (2004) (2)
- 1223PDQuality-adjusted survival of combined nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone vs IPI among treatment-naïve patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis (2017) (2)
- Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients. (2018) (2)
- Efficacy and safety of high-dose interleukin-2 treatment in patients with a history of brain metastases from renal cell carcinoma (2015) (2)
- Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2). (2016) (2)
- High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes. (2014) (2)
- Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC. (2022) (2)
- TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC). (2021) (2)
- Safety and activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma: A cytokine working group phase II study. (2018) (2)
- Abstract 3639: Matching-adjusted indirect comparison of nivolumab + ipilimumab and BRAF+MEK inhibitors for the treatment of BRAF-mutant treatment-naive advanced melanoma (2018) (2)
- Treatment discontinuations, dose reductions, and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC) (2008) (2)
- Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST. (2018) (2)
- Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (2022) (2)
- What Is Standard Initials Systemic Therapy in Metastatic Renal Cell Carcinoma (2007) (2)
- Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy (2008) (2)
- Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study. (2020) (2)
- Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC). (2019) (2)
- Lymphodepletion with high-dose interleukin-2 (IL-2) and granulocyte macrophage-colony stimulating factor (GM-CSF) in metastatic melanoma patients: An interim analysis. (2006) (2)
- Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. (2011) (2)
- Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH). (2021) (2)
- Use of immune checkpoint inhibitors (ICIs) after prior ICI in metastatic renal cell carcinoma (mRCC): Results from a multicenter collaboration. (2020) (1)
- A retrospective analysis of high-dose aldesleukin (HD IL-2) following immune checkpoint blockade (ICB) in metastatic melanoma (MM) and metastatic renal cell carcinoma (mRCC). (2015) (1)
- Carbonic Anyhydrase IX (CAIX) Expression Does Not Correlate with the Renal Cell Cancer (RCC) Patient Response to CCI-779 (2004) (1)
- First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis (2021) (1)
- Estimating treatment-free survival (TFS) over extended follow-up in patients (pts) with advanced melanoma (MEL) treated with immune-checkpoint inhibitors (ICIs): Five-year follow-up of CheckMate 067. (2020) (1)
- Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: analysis of data on the current use of HD IL-2 (2015) (1)
- Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC). (2015) (1)
- Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. (2020) (1)
- PD1 and PD-L1 Immune Checkpoint Inhibitors in Gastrointestinal Cancer (2017) (1)
- The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). (2016) (1)
- Vaccination with DC/RCC fusions following cytoreductive nephrectomy. (2010) (1)
- A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation. (2009) (1)
- Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival. (2016) (1)
- The Effect of Surgical Debulking on the Response of Patients with Ovarian Carcinoma to Chemotherapy (1988) (1)
- 9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases (2011) (1)
- First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up for KEYNOTE-427 cohort A. (2020) (1)
- A phase I study of buparlisib (BKM120) with bevacizumab (BEV) in patients (pts) with metastatic renal cell carcinoma (mRCC) progressing on prior vascular endothelial growth factor (VEGF) therapies. (2015) (1)
- TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). (2019) (1)
- Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study. (2023) (1)
- Efficacy of targeted therapies after PD1/PD-L1 inhibitors in metastatic clear cell renal cell carcinoma (mRCC): A multi-institution retrospective cohort. (2015) (1)
- Are immune checkpoint combination therapies for intermediate and poor risk renal cell carcinoma better than immune checkpoint inhibitors combined with kinase inhibitors? (2021) (1)
- Concordance of local pathology interpretation (LR) with central pathology review (CR) in primary tumor specimens from patients with renal cancer (RCC). (2004) (1)
- A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM). (2013) (1)
- Gene Expression Patterns Associated with Renal Cancer (RCC) Response and Resistance to IL-2-Based Therapy (2004) (1)
- Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3 (2022) (1)
- Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. (2020) (1)
- Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC. (2021) (1)
- Melanoma Brain Metastases Treated With Brain-directed Radiation Followed by Ipilimumab (2012) (1)
- Stable disease after high dose interleukin-2 (HD IL-2) immunotherapy: observations on long term survival and clinical benefit of additional HD IL-2 (2014) (1)
- Phase Ib study to test the safety and activity of pembrolizumab (anti-PD-1) and trebananib (angiopoietin-2 inhibitor [Ang-2]) in patients with advanced solid tumors: Updated analysis of the colorectal cancer (CRC) cohort. (2020) (1)
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) (1)
- Markers of inflammation are associated with clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (2015) (1)
- Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition. (2012) (1)
- High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry. (2018) (1)
- Integrating palliative care into care of patients with kidney cancer and melanoma. (2014) (1)
- 767O TREATMENT OF PATIENTS WITH ADVANCED REFRACTORY OR RELAPSED MELANOMA IN A PHASE II STUDY OF TREMELIMUMAB (CP-675,206), AN ANTI-CTLA4 MONOCLONAL ANTIBODY (2008) (1)
- Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy (2019) (1)
- Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. (2018) (1)
- 896PA Phase (Ph) 1 dose finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC) (2017) (1)
- Factors associated with worse outcome for patients with AJCC stage IIC relative to stage IIIA melanoma. (2015) (1)
- 424 A phase 1b/2 randomized study of AVB-S6–500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment (2021) (1)
- 7004 ORAL Phase II randomized, placebo controlled study of sorafenib in combination with dacarbazine in subjects with unresectable Stage III or Stage IV melanoma (2007) (1)
- High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates (2013) (1)
- Soluble PD-L1 as a marker of progressive disease on nivolumab in kidney cancer. (2020) (0)
- High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade (2020) (0)
- Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2 (2016) (0)
- PCN50 COSTS OF TREATMENT WITH ANGIOGENESIS INHIBITORS (AIS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC): RESULTS FROM A MEDICAL CHART REVIEW STUDY (2010) (0)
- Immune Reconstitution Following Reduced Intensity Conditioning With CAMPATH-1H Versus Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior To Allogeneic Stem Cell Transplantation (2010) (0)
- Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial (2022) (0)
- Improving end-of-life care: Palliative care embedded in an outpatient oncology clinic. (2017) (0)
- Biomarker analysis from the phase 3 CheckMate 9ER trial of nivolumab + cabozantinib v sunitinib for advanced renal cell carcinoma (aRCC). (2023) (0)
- Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC). (2019) (0)
- Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) (2023) (0)
- Quality of life (QoL) and symptom burden in patients (pts) with advanced melanoma during the treatment-free interval (TFI) after discontinuation of nivolumab (NIVO) or NIVO plus ipilimumab (IPI). (2019) (0)
- Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy. (2021) (0)
- 817PPROGNOSTIC IMPACT OF CHANGE IN NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IN RESPONSE TO TARGETED THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC). (2014) (0)
- Evaluating the Impact of Sentinel Node Biopsy in Merkel Cell Carcinoma (2016) (0)
- Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2020) (0)
- Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma (2023) (0)
- Patient Reported Toxicities from Molecularly Targeted Therapies in Renal Cell Carcinoma (RCC) (2007) (0)
- Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval (2022) (0)
- Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry. (2015) (0)
- Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A). (2023) (0)
- Abstract 3827: NCI 8628 - A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma (2017) (0)
- Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy. (2023) (0)
- 556 Extracellular matrix (ECM) biomarkers are elevated in advanced renal cell carcinoma (aRCC) and predictive of response to nivolumab plus ipilimumab (NIVO+IPI): analysis from CheckMate 214 (2022) (0)
- Update on theApplication of Interleukin-2 in theTreatment of Renal Cell Carcinoma (2007) (0)
- 349 Tolerability of tivozanib vs. sorafenib in elderly and/or immunotherapy-pretreated patients with metastatic renal cell cancer (mRCC) in TIVO-3 (2021) (0)
- Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A. (2020) (0)
- A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results. (2012) (0)
- Sensitivity of treatment-free survival (TFS), a novel outcome, to subgroup analyses of patients (pts) with advanced melanoma (MEL) treated with immune checkpoint inhibitors (ICI). (2019) (0)
- Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States (2021) (0)
- Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers (2023) (0)
- Durability of responses in patients with metastatic renal cell carcinoma treated with high dose interleukin-2 (HD IL-2) (2015) (0)
- Abstract CT093: Axitinib in combination with pembrolizumab (AXI+PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers (2019) (0)
- 9306 Phase II multi-institution trial of ipilimumab for patients with melanoma and brain metastasis (2009) (0)
- Immune Checkpoint Inhibitors (Anti-CTLA4, Anti-PD-1) in RCC (2015) (0)
- Cytokine therapy for cancer (2011) (0)
- 44IN IMMUNOTHERAPY: MYTH OR REALITY? (2014) (0)
- Renal cell carcinoma: The effect of targeted therapies on clear cell and non-clear cell histologies. (2016) (0)
- Q-TWiST analysis of tivozanib (T) versus sorafenib (S) in patients with advanced renal cell carcinoma (RCC) in the TIVO-3 study. (2021) (0)
- Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (2021) (0)
- The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2). (2017) (0)
- Real-world outcomes with immuno-oncology (IO) therapies: A prospective, observational cohort study in patients (pts) with advanced melanoma (OPTIMIzE). (2019) (0)
- Early Detection of Response to Antiangiogenic Therapy in Metastatic Clear-cell Renal Cell Carcinoma with ASL MRI (2008) (0)
- Association between mitotic rate and lymph node metastasis in thin melanoma in the general population.. (2014) (0)
- LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma. (2023) (0)
- 2022-RA-588-ESGO Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients with advanced solid tumours: ARTISTRY-1 (2022) (0)
- Abstract CT244: A phase 1a/1b study of STK-012, an α/β IL-2 receptor selective partial agonist as monotherapy and in combination with pembrolizumab in advanced solid tumors (NCT05098132) (2022) (0)
- Genetic polymorphisms’ influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents. (2012) (0)
- Patterns of Screening in Cervical and Colorectal Cancer in a Rural Appalachian Setting (2020) (0)
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023) (0)
- Statin use and risk of renal cell carcinoma in three prospective cohort studies. (2018) (0)
- TIVO-3: Age-related tolerability outcomes of tivozanib versus sorafenib in metastatic relapsed or refractory renal cell carcinoma, a subgroup analysis of the TIVO-3 clinical trial. (2021) (0)
- Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors (2021) (0)
- Companion Diagnostics and Cancer Biomarkers Clinical Utility of a Blood-Based BRAFV 600 EMutation Assay in Melanoma (2014) (0)
- A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma (2023) (0)
- IL-2 and Other Immunotherapy in Renal Cancer (2011) (0)
- FDA pooled analysis of time to treatment discontinuation (TTD) in frontline advanced renal cell carcinoma trials. (2020) (0)
- Feasibility and Implementation of a Free-of-Cost Community Based Comprehensive Cancer Screening Program (2020) (0)
- Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2) (2015) (0)
- Cancer Therapy : Clinical Multicenter , Phase II Study of Axitinib , a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1 , 2 , and 3 , in Patients with Metastatic Melanoma (2011) (0)
- Circulating mir-21 and mir-378 are predictive of progression-free survival (PFS) in patients treated with everolimus in metastatic renal cell cancer (mRCC). (2012) (0)
- Subject Index Vol. 78, 2010 (2010) (0)
- The right questions to ask in new trials of immunotherapy. (2015) (0)
- Contents Vol. 78, 2010 (2010) (0)
- Frontline Immunotherapy/Bevacizumab Ups PFS in PD-L1–Positive mRCC (2017) (0)
- Clinical Utility of a Blood-Based BRAFMutation Assay in Melanoma (2014) (0)
- Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade (2021) (0)
- A phase II biomarker trial of everolimus in patients with advanced renal cell carcinoma (08-313). (2014) (0)
- 176 Successful generation of tumor-infiltrating lymphocyte (TIL) product from renal cell carcinoma (RCC) tumors for adoptive cell therapy (2021) (0)
- Oncologic Outcome of Bimodality Approach for Cutaneous Adnexal Carcinoma (2016) (0)
- Bevacizumab in Combination with Interferon Alpha in Metastatic Renal Cell Carcinoma: The Emerging Evidence of Its Therapeutic Value (2011) (0)
- Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer. (2022) (0)
- Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group study. (2017) (0)
- Phase I T rial o f C oncurrent T wice-Weekly R ecombinant Human I nterleukin-12 P lus L ow-Dose I L-2 i n P atients W ith Melanoma o r R enal C ell C arcinoma (2003) (0)
- 219 Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients (2020) (0)
- 44INIMMUNOTHERAPY: MYTH OR REALITY? (2014) (0)
- Abstract CT120: The randomized phase 1/2 LITESPARK-024 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma (RCC) (2023) (0)
- Adjuvant H igh-Dose B olus I nterleukin-2 f or P atients W ith High-Risk R enal C ell C arcinoma: A C ytokine W orking G roup Randomized T rial (2003) (0)
- Impact of integrated palliative care model on end-of-life (EOL) quality metrics for patients with kidney cancer (RCC) and melanoma (M). (2015) (0)
- experimental visceral leishmaniasis. Th1 and Th2 cell-associated cytokines in (2013) (0)
- 662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B (2021) (0)
- 1471P Plasma KIM-1 for preoperative identification and risk stratification of renal cell carcinoma (2022) (0)
- A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma. (2015) (0)
- A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC). (2014) (0)
- 347 Clinical outcomes of ovarian cancer patients treated with ALKS 4230, a novel engineered cytokine, in combination with pembrolizumab: ARTISTRY-1 trial (2020) (0)
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (2020) (0)
- Response of Extracranial Lesions After Treatment of Metastatic Melanoma With Cranial Radiation and Ipilimumab (2014) (0)
- Patient-reported side effects from molecularly targeted therapies in renal cell carcinoma (RCC). (2010) (0)
- Integrating a paradigm shift into treatment of renal cell cancer: Effect of online CME on oncologists' knowledge and competence. (2018) (0)
- Nivolumab vs. Everolimus (2016) (0)
- Combination therapy for renal cell carcinoma: review of the clinical evidence (2011) (0)
- Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry. (2017) (0)
- Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC). (2019) (0)
This paper list is powered by the following services:
